Natixis Neurocrine Biosciences Inc Transaction History

Natixis

$17.6 Billion
Q3 2024

A detailed history of Natixis transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Natixis holds 567 shares of NBIX stock, worth $71,164. This represents 0.0% of its overall portfolio holdings.

Number of Shares

567

Previous 1,139 50.22%

Holding current value

$71,164

Previous $156,000 58.33%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$114.58 - $153.15 $65,539 - $87,601	-572 Reduced 50.22%	567 $65,000
Q2 2024 Aug 13, 2024	SELL	$130.86 - $143.19 $57,840 - $63,289	-442 Reduced 27.96%	1,139 $156,000
Q1 2024 May 13, 2024	SELL	$130.4 - $143.74 $42,119 - $46,428	-323 Reduced 16.96%	1,581 $218,000
Q4 2023 Feb 13, 2024	SELL	$106.07 - $132.76 $61,308 - $76,735	-578 Reduced 23.29%	1,904 $250,000
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $1.88 Million - $2.34 Million	-19,944 Reduced 88.93%	2,482 $279,000
Q2 2023 Aug 11, 2023	BUY	$89.53 - $104.87 $537,269 - $629,324	6,001 Added 36.54%	22,426 $2.11 Million
Q1 2023 May 12, 2023	SELL	$94.11 - $123.02 $2.66 Million - $3.47 Million	-28,224 Reduced 63.21%	16,425 $1.66 Million
Q4 2022 Feb 24, 2023	BUY	$106.72 - $127.06 $2.29 Million - $2.73 Million	21,500 Added 92.88%	44,649 $5.33 Million
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $2.47 Million - $2.94 Million	23,149 New	23,149 $2.76 Million
Q2 2022 Aug 12, 2022	SELL	$75.79 - $100.07 $85,566 - $112,979	-1,129 Reduced 34.73%	2,122 $208,000
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $39,340 - $51,481	-543 Reduced 14.31%	3,251 $305,000
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $31,860 - $42,488	-400 Reduced 9.54%	3,794 $323,000
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $278,361 - $319,866	-3,230 Reduced 43.51%	4,194 $402,000
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $663,928 - $759,252	7,424 New	7,424 $723,000
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $352,907 - $481,182	-4,030 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $350,247 - $436,569	4,030 New	4,030 $386,000
Q3 2020 Nov 12, 2020	SELL	$96.16 - $135.15 $358,869 - $504,379	-3,732 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $317,555 - $486,503	3,732 New	3,732 $455,000
Q1 2020 May 14, 2020	SELL	$75.11 - $113.76 $459,748 - $696,324	-6,121 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $531,302 - $725,766	6,121 New	6,121 $656,000
Q2 2019 Aug 13, 2019	SELL	$72.24 - $91.27 $660,779 - $834,846	-9,147 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $284,240 - $375,364	-4,101 Reduced 30.96%	9,147 $783,000
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $96,399 - $175,471	1,411 Added 11.92%	13,248 $946,000
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $1.17 Million - $1.49 Million	11,837 New	11,837 $1.46 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account